RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Arbutus Biopharma Stock

Arbutus Biopharma Market capitalization 2024

Arbutus Biopharma Market capitalization

635.63 M USD

Ticker

ABUS

ISIN

CA03879J1003

WKN

A14XMD

In 2024, Arbutus Biopharma's market cap stood at 635.63 M USD, a 104.48% increase from the 310.84 M USD market cap in the previous year.

The Arbutus Biopharma Market capitalization history

YEARMarket Capitalization (undefined USD)
2023392.86
2022390.8
2021380.74
2020206.67
2019138.01
2018361.27
2017223.99
2016194.08
2015564.02
2014354.76
201389.37
201243.97
201133.42
201059.3
200944.77
200833.28
200730.54
2006-
2005-
2004-

Arbutus Biopharma Aktienanalyse

What does Arbutus Biopharma do?

Arbutus Biopharma Corp is a biopharmaceutical company that focuses on developing novel treatment methods for viral diseases. The company, based in Vancouver, Canada, was founded in 2008. The history of Arbutus Biopharma Corp began with the merger of Tekmira Pharmaceuticals and OnCore Biopharma in 2015. The merger strengthened the company and expanded its ability to develop innovative therapies for Hepatitis B and Hepatitis D viruses. The ability to bring the companies together also demonstrates the team, consisting of experienced experts from various areas such as the healthcare industry, biotech engineering, finance, and pharmacy. The business model of Arbutus Biopharma Corp is to explore, develop, and market novel treatment methods for viral diseases. Marketing is done through partnerships with other companies that commercialize the products. The company relies on research and development agreements to enter into synergistic partnerships that work on the same wavelength. One of the key divisions of Arbutus Biopharma Corp is the development of RNA interference (RNAi) therapies. These therapies aim to suppress the genetic information that leads to viral replication in cells. The company has an extensive patent portfolio and comprehensive expertise in the field of RNAi therapy. RNAi therapy opens up a new paradigm in the treatment of viral diseases. The company has also developed products such as the HBV Antisense platform. The HBV Antisense platform utilizes a special type of RNA-based medication to suppress the production of proteins necessary for the replication of the Hepatitis B virus. This strategy allows for the reduction of viral RNA replication and strengthens the immune system to fight against or prevent viral infections. The company also pursues an advanced pipeline in the preclinical phase to develop a melanocortin receptor antagonist and an artificial antibody against Hepatitis B. Another business area of Arbutus Biopharma Corp is collaboration with other companies to outsource innovative technologies and products. One of the key partnerships is with Roivant Sciences Ltd. Roivant Sciences Ltd is a pharmaceutical company that focuses on the development and commercialization of innovative therapy approaches. The partnership between Arbutus Biopharma Corp and Roivant Sciences Ltd creates a win-win situation for both, bringing about synergies and enabling capital and risk sharing. In summary, Arbutus Biopharma Corp is a biopharmaceutical company that focuses on the development of novel therapies for viral diseases. The company has a broad portfolio of innovative products in the field of RNAi therapy and HBV Antisense platform. Arbutus Biopharma Corp strives to achieve advancements in the development of therapies for viral diseases through partnerships and alliances with other companies. Arbutus Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Arbutus Biopharma's Market Capitalization

Arbutus Biopharma's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Arbutus Biopharma's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Arbutus Biopharma's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Arbutus Biopharma’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Arbutus Biopharma stock

What is the current Arbutus Biopharma market capitalization?

The current market capitalization of Arbutus Biopharma is 635.63 M USD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Arbutus Biopharma.

How has the market capitalization of Arbutus Biopharma developed in recent years?

The market capitalization of Arbutus Biopharma has increased/decreased by 104.48% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Arbutus Biopharma?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Arbutus Biopharma?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Arbutus Biopharma have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Arbutus Biopharma pay?

Over the past 12 months, Arbutus Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Arbutus Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of Arbutus Biopharma?

The current dividend yield of Arbutus Biopharma is .

When does Arbutus Biopharma pay dividends?

Arbutus Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Arbutus Biopharma?

Arbutus Biopharma paid dividends every year for the past 0 years.

What is the dividend of Arbutus Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Arbutus Biopharma located?

Arbutus Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Arbutus Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Arbutus Biopharma from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Arbutus Biopharma pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Arbutus Biopharma in the year 2023?

In the year 2023, Arbutus Biopharma distributed 0 USD as dividends.

In which currency does Arbutus Biopharma pay out the dividend?

The dividends of Arbutus Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Arbutus Biopharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Arbutus Biopharma

Our stock analysis for Arbutus Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Arbutus Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.